Actively Recruiting
Phase 1 Study of JANX013 Combined With JANX007 for Metastatic Castration-Resistant Prostate Cancer
Led by Janux Therapeutics · Updated on 2026-09-17
110
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a first-in-human, Phase 1, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination of JANX013 and JANX007 in adult males with metastatic castration-resistant prostate cancer mCRPC. This study focuses on patients with advanced prostate cancer resistant to standard hormone therapies and prior treatments, aiming to explore new treatment options. Participants will receive both JANX013 and JANX007 through intravenous dosing. The study includes two key phases a dose escalation phase where increasing dose levels are tested for safety and tolerability, and a dose expansion phase where participants are treated at previously tolerated dose levels. This approach helps determine the appropriate dosage and gathers initial data on the effects of the drug combination. During the study, participants will be closely monitored for adverse events, including serious and dose-limiting toxicities, and cytokine release syndrome for up to two years. Researchers will also evaluate drug levels in the blood, immune response against the drugs, prostate-specific antigen levels, radiographic progression-free survival, duration of response, and disease control rate. The trial involves regular assessments and safety follow-up over a two-year period to collect comprehensive information about the treatments impact and tolerability.
CONDITIONS
Brief Title
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
Research Team
J
Janux Therapeutics, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here